Sven de Vos - Concepedia

Author

Sven de Vos

University of California, Los Angeles ORCID

Also Known As

De Vos, Sven, S De Vos, S de Vos, S. De Vos, S. de Vos, SVEN DE VOS, Sven De Vos, Sven de Vos

360

Publications

16.5K

Citations

H-Index

112

Concepts

All Affiliations

University of California, Los Angeles The University of Texas MD Anderson Cancer Center Cornell University Sarah Cannon Memorial Sloan Kettering Cancer Center

About

Sven de Vos is an author at University of California, Los Angeles specializing in medicine, immunology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	25	45	4.2K
2	Health Sciences	12	13	671
3	Education	1	1	26
4	Natural Sciences	1	1	59
5	Public Health	1	1	26

Sven de Vos

145

Publications

15.2K

Citations

H-Index

Page 1

	Year	Citations
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia John C. Byrd, Jennifer R. Brown, Susan O’Brien, New England Journal of Medicine	2014	1.6K
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma Anas Younes, Ajay K. Gopal, Scott E. Smith, Journal of Clinical Oncology	2012	1.5K
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma Wyndham H. Wilson, Ryan M. Young, Roland Schmitz, Nature Medicine Lymphoid NeoplasiaMedicineImmunologyPathologyImmune Checkpoint Inhibitor	2015	1.1K
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma Ajay K. Gopal, Brad S. Kahl, Sven de Vos, New England Journal of Medicine	2014	1K
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Jonathan W. Friedberg, Jeff P. Sharman, John Sweetenham, Blood	2009	734
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell Lymphoma Richard I. Fisher, Steven H. Bernstein, Brad S. Kahl, Journal of Clinical Oncology	2006	705
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial Caron A. Jacobson, Julio C. Chávez, Alison R. Sehgal, The Lancet Oncology Lymphoid NeoplasiaAxicabtagene CiloleucelMedicinePathologyPharmacotherapy	2021	574
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study André Goy, Steven H. Bernstein, Brad S. Kahl, Annals of Oncology Hematological MalignancyLymphoid NeoplasiaHealth SciencesUpdated Time-to-event AnalysesMedicine	2008	340
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma Ariela Noy, Sven de Vos, Catherine Thiéblemont, Blood	2017	283
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial Sattva S. Neelapu, Michael Dickinson, Javier Muñoz, Nature Medicine	2022	266

Page 1